Analyst Price Target is $10.50
▲ +140.83% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anixa Biosciences in the last 3 months. The average price target is $10.50, with a high forecast of $12.00 and a low forecast of $9.00. The average price target represents a 140.83% upside from the last price of $4.36.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Anixa Biosciences.
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.